INDIANAPOLIS, Sept. 28, 2015 /PRNewswire/ -- Eli Lilly and
Company (NYSE: LLY) has entered into a settlement agreement to
resolve patent litigation with Sanofi regarding its insulin
glargine product, Basaglar®. As a part of the agreement, Lilly and
its alliance partner, Boehringer Ingelheim, will have the ability
to launch Basaglar in the U.S. on December
15, 2016. Under the terms of the agreement, Sanofi has
granted Lilly a royalty-bearing license so Lilly can manufacture
and sell Basaglar in the Kwikpen® device globally. Further details
regarding the settlement are confidential.
The U.S. Food and Drug Administration tentatively approved
Basaglar in August 2014. With this
resolution, Lilly plans to request final approval of Basaglar from
the FDA.
"The settlement agreement ends the legal dispute between Lilly
and Sanofi and provides us with certainty as it relates to our U.S.
launch timing," said Michael J.
Harrington, senior vice president and general counsel for
Lilly. "This enables us to focus our efforts on preparing to
successfully market and launch Basaglar in the U.S. in December of
2016."
About Eli Lilly and Company
Lilly is a global
healthcare leader that unites caring with discovery to make life
better for people around the world. We were founded more than a
century ago by a man committed to creating high-quality medicines
that meet real needs, and today we remain true to that mission in
all our work. Across the globe, Lilly employees work to discover
and bring life-changing medicines to those who need them, improve
the understanding and management of disease, and give back to
communities through philanthropy and volunteerism. To learn more
about Lilly, please visit us at www.lilly.com and
http://newsroom.lilly.com/social-channels. C-LLY
This release contains forward-looking statements regarding U.S.
insulin glargine patent litigation and related settlement.
There can be no guarantees as to the outcome of the settlement, nor
are there any guarantees that Lilly's insulin glargine product will
be commercially successful. These statements are based on
management's current expectations, but actual results may differ
materially. Other risk factors that may affect the company's
results can be found in the company's latest Forms 10-K and 10-Q
filed with the U.S. Securities and Exchange Commission
Refer
to:
|
Lauren Zierke;
lauren_zierke@lilly.com; +1 317-277-6524 (Media)
|
|
Phil Johnson;
johnson_philip_l@lilly.com; +1 317-655-6874 (Investors)
|
Logo -
http://photos.prnewswire.com/prnh/20031219/LLYLOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/lilly-and-sanofi-reach-settlement-agreement-in-us-insulin-glargine-litigation-300149810.html
SOURCE Eli Lilly and Company